The current report suggests that the concurrent targeting of GLP-1 secretion and the TXNIP–thioredoxin system by microbial metabolites presents a powerful, holistic strategy to address both the hormonal and oxidative components of MetS. This evidence concerns the gene TXNIP and metabolic syndrome.